Clinical Trial Detail

NCT ID NCT02989714
Title Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

clear cell renal cell carcinoma

Therapies

Aldesleukin + Nivolumab

Age Groups: adult senior

No variant requirements are available.